Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist Training with First Multi-Dose Psilocybin Trial in Canada
Achieved milestone with the start of landmark psilocybin clinical trial in Q3 2021- more than a dozen patients receive initial dose to date in first-ever...
Source: prnewswire.com